Osteoarthritis is the most common form of arthritis and is a major cause of disability in the elderly population. It affects more than 500 million people world-wide and with no cure, OA constitutes a considerable unmet medical need.
NBCD is a full service CRO specialized in OA. With our expertise in clinical trial design and placebo response mitigation, we have worked with the different sponsors to successfully conduct several phase I, II and III trials within both OA pain and DMOAD compounds. NBCD has led large clinical programs to FDA approval and has become the leading CRO in the OA space.
Through the years, we have been successfully inspected by FDA, EMA and national European Agencies. As an organization, we are driven by science and conduct our own data-gap projects to gain additional insight to the relevant conditions, and elements of particular interest to trial design. NBCD has also been pioneering the field of risk-based monitoring, gaining 10+ years of experience with the method, leading to improved data quality.
NBCD offers all aspects of clinical operations for life science companies. We provide expert consultancy and strategic partnership throughout all the clinical phases.
At NBCD, our approach is partner-centric, and we tailor our unique solutions to our clients’ needs.
NBCD has extensive operational and scientific expertise in conducting osteoarthritis trials. We know the disease better than any other company and have enrolled more than 15,000 patients in phase I, II and III trials.
NBCD employs 45 people worldwide and are conducting clinical trials globally through our own employees and long-term strategic partners. Our stronghold is in Europe and USA, but we also operational in Asia, Latin America and Australia.
